Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer

Area of Science:

• Oncology
• Metabolic pathways
• Cancer biology

Background:

• Metabolic remodeling is a recognized hallmark of cancer.
• The specific metabolic strategies frequently exploited by diverse tumors remain unclear.
• Understanding cancer-specific metabolic alterations is crucial for therapeutic development.

Purpose of the Study:

• To identify consistently differentially expressed metabolic enzymes across a wide range of cancer types.
• To investigate the role of specific metabolic pathways, particularly mitochondrial one-carbon metabolism, in cancer.
• To uncover potential new therapeutic targets in cancer metabolism.

Main Methods:

• Meta-analysis of messenger RNA (mRNA) profiles for 1,454 metabolic enzymes.
• Analysis across 1,981 tumors representing 19 distinct cancer types.
• Correlation of enzyme expression with patient survival data, specifically in breast cancer.

Main Results:

• Identified consistently differentially expressed metabolic enzymes, including known chemotherapeutic targets like dihydrofolate reductase.
• Highlighted novel enzymes such as PYCR1 (proline biosynthesis) and MTHFD2 (mitochondrial one-carbon metabolism).
• MTHFD2 was found to be markedly elevated in many cancers, associated with poor survival in breast cancer, and absent in most healthy adult tissues.

Conclusions:

• MTHFD2 is a promising cancer-specific target due to its elevated expression in tumors and association with poor prognosis.
• Mitochondrial compartmentalization of one-carbon metabolism plays a significant role in cancer.
• The findings provide a strong basis for developing novel therapeutic strategies targeting cancer metabolism.